Researchers identify therapy that shrinks tumors in patients with multiple myeloma

Researchers identify therapy that shrinks tumors in patients with multiple myeloma
Credit: Mayo Clinic

Mayo Clinic researchers have found that an experimental drug, LCL161, stimulates the immune system, leading to tumor shrinkage in patients affected by multiple myeloma. The findings are published in Nature Medicine.

Multiple myeloma is a blood cancer that affects - that normally produce antibodies to fight infection. Rather than produce helpful antibodies, the cancer cells, as they grow, secrete large amounts of a single antibody that accumulate in the body, causing kidney problems and infections.

"The drug, LCL161, was initially developed to promote tumor death," says Marta Chesi, Ph.D., a Mayo Clinic biochemist and lead author of the study of 25 Multiple Myeloma patients. "However, we found that the drug does not kill directly. Rather, it makes them more visible to the immune system that recognizes them as foreigner invaders and eliminates them."

Mayo Clinic researchers will conduct a follow-up clinical trial of LCL161 in combination with an inhibitor of immune checkpoints that has been widely used in many cancer treatments to evaluate if LCL161 could represent a potential new treatment option.

"The model for preclinical studies to predict with great accuracy which drugs would work in the clinic was developed a decade ago," says Dr. Chesi. "And it has been instrumental in the prioritization of which experimental therapeutics should be tested in patients with multiple myeloma."

The research highlights the importance of studying the effects of drugs not only on the tumor cells in a culture plate, but also on the interaction of the tumor cells with their own microenvironment. The finding that LCL161 is active against suggests that similar drugs may have broader clinical activity than previously thought.


Explore further

New treatments to extend life for multiple myeloma patients

More information: Marta Chesi et al. IAP antagonists induce anti-tumor immunity in multiple myeloma, Nature Medicine (2016). DOI: 10.1038/nm.4229
Journal information: Nature Medicine

Provided by Mayo Clinic
Citation: Researchers identify therapy that shrinks tumors in patients with multiple myeloma (2017, March 8) retrieved 24 June 2019 from https://medicalxpress.com/news/2017-03-therapy-tumors-patients-multiple-myeloma.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more